29 - Antiviral drugs
Section snippets
Skin
Topical cidofovir 1–3% has been successfully used for the treatment of oral warts in three HIV-positive patients with no adverse effects (1A). However, ulceration and pain at the site of the lesion, leaving the normal skin unharmed, were reported as the main adverse effect after topical application to high-grade vulval intraepithelial neoplasia in 12 women (2A).
Topical cidofovir 1% has also been used in the successful treatment of a refractory verruca in a child with acute lymphoblastic
Nervous system
It has been suggested that hemodialysis can be a useful diagnostic tool in the differential diagnosis between aciclovir-induced neurotoxicity and herpes encephalitis, as well as a fast and reliable treatment of drug-induced neurotoxicity (6A).
- •
A previously healthy 59-year-old woman developed right eye pain for 3 days and vesicle formation on her forehead. She received intravenous aciclovir 250 mg every 8 hours, but 48 hours later she became drowsy and lethargic, with incoherent speech and
Observational studies
A total of 49 consecutive lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B patients were enrolled in a study of the effects of adefovir 10 mg/day plus lamivudine 100 mg/day (8C). After 52 weeks all had some hepatitis B virus DNA response and 57% had a complete virological response. There was a biochemical response in 76%. There were no serious adverse events.
Entecavir
Entecavir recently received FDA approval in the USA for use in treatment-naïve hepatitis B e antigen (HBeAg) positive
Pleconaril
In a placebo-controlled study of pleconaril in 827 patients with positive baseline nasal mucus cultures for rhinoviruses, those who were infected with viruses that are more highly susceptible to pleconaril (50% effective concentration <0.38 μg/ml) had a median 1.9–3.9 day reduction in symptom duration compared with placebo (65C). In contrast, subjects whose baseline virus isolate susceptibility was >0.38 μg/ml did not benefit from pleconaril. Adverse effects were not mentioned.
References (65)
- et al.
Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia
Gynecol Oncol
(2005) - et al.
Emergent hemodialysis for acyclovir toxicity
Am J Emerg Med
(2005) - et al.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
Lancet
(2005) - et al.
Should living donor liver transplantation be offered to patients with hepatitis C virus cirrhosis?
J Hepatol
(2005) - et al.
Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature
Arch Dermatol
(2005) - et al.
Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases
J Clin Endocrinol Metab
(2005) - et al.
Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses
Antimicrob Agents Chemother
(2005) - et al.
Refractory human papillomavirus-associated oral warts treated topically with 1–3% cidofovir solutions in human immunodeficiency virus type 1-infected patients
Br J Dermatol
(2005) - et al.
Successful treatment of a refractory verruca in a child with acute lymphoblastic leukaemia with topical cidofovir
Br J Dermatol
(2005) - et al.
Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients
Clin Infect Dis
(2005)